A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ERα expressing primary and metastatic invasive ductal carcinoma

Targeting tumor cell metabolism is a new frontier in cancer management. Thus, metabolic pathway inhibitors could be used as anti-estrogen receptor α (ERα) breast cancer (BC) drugs. Here, the interplay among metabolic enzyme(s), the ERα levels and cell proliferation was studied. siRNA-based screen di...

Descripción completa

Detalles Bibliográficos
Autores principales: Cipolletti, Manuela, Leone, Stefano, Bartoloni, Stefania, Acconcia, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151738/
https://www.ncbi.nlm.nih.gov/pubmed/37143728
http://dx.doi.org/10.3389/fendo.2023.1129162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151738/
https://www.ncbi.nlm.nih.gov/pubmed/37143728
http://dx.doi.org/10.3389/fendo.2023.1129162

Ejemplares similares